Vivo Bio Tech . Falls to 52-Week Low of Rs.30.99 Amidst Continued Downtrend

On 19 Nov 2025, Vivo Bio Tech . recorded its lowest price in the past year at Rs.30.99, continuing a losing streak that has spanned five consecutive trading sessions. Over this period, the stock has delivered a negative return of 9.81%, underperforming the Pharmaceuticals & Biotechnology sector by 2.01% on the day. This decline contrasts with the broader market, where the Sensex rose by 0.4% to close at 85,010.04, approaching its own 52-week high of 85,290.06.

The stock’s current trading levels are below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent downward momentum. This technical positioning suggests that Vivo Bio Tech . has been facing sustained selling pressure relative to its historical price trends.

Over the last year, Vivo Bio Tech . has generated a return of -21.59%, a stark contrast to the Sensex’s positive 9.58% return over the same period. The stock’s 52-week high was Rs.56.90, indicating a substantial decline from its peak price. This performance reflects ongoing challenges in maintaining competitive positioning within the Pharmaceuticals & Biotechnology sector.

From a fundamental perspective, Vivo Bio Tech . has exhibited a compound annual growth rate (CAGR) of net sales at -0.92% over the past five years, indicating a contraction in revenue generation. The company’s ability to service its debt is reflected in an average EBIT to interest ratio of 1.95, which suggests limited coverage of interest expenses by operating earnings. Profitability metrics also highlight challenges, with an average return on equity (ROE) of 7.49%, pointing to modest returns on shareholders’ funds.

In addition to the recent price decline, the stock has consistently underperformed the BSE500 index across the last three annual periods. This trend underscores the relative weakness of Vivo Bio Tech . compared to a broad market benchmark, further emphasising the stock’s subdued performance within its sector.

Despite these headwinds, the company reported some positive financial results in the six months ending June 2025. Profit after tax (PAT) stood at Rs.2.40 crore, reflecting a growth rate of 163.74% compared to the previous corresponding period. Quarterly net sales reached a high of Rs.12.51 crore, while the operating profit to interest coverage ratio for the quarter was recorded at 3.65 times, the highest in recent periods. These figures indicate pockets of operational improvement amid broader challenges.

Valuation metrics present a mixed picture. Vivo Bio Tech . has a return on capital employed (ROCE) of 9.3%, which is considered attractive relative to some peers. The enterprise value to capital employed ratio stands at 0.9, suggesting the stock is trading at a discount compared to average historical valuations within the Pharmaceuticals & Biotechnology sector. However, over the past year, profits have declined by 42.5%, which may temper valuation considerations.

Ownership structure reveals that the majority shareholders are non-institutional investors, which may influence liquidity and trading dynamics. The stock’s market capitalisation grade is rated at 4, reflecting its micro-cap status within the Pharmaceuticals & Biotechnology sector.

In summary, Vivo Bio Tech .’s fall to a 52-week low of Rs.30.99 is the result of a combination of subdued financial growth, limited debt servicing capacity, and consistent underperformance relative to market benchmarks. While recent quarterly results show some improvement in profitability and sales, the stock remains below key technical levels and continues to trade at a discount to historical valuations. The broader market environment, with the Sensex trading near its 52-week high and supported by mega-cap gains, contrasts with the stock’s current trajectory.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →